<p>Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. He<br>
describes the options available for prophylaxis and how he treats the toxicities that do arise.</p>


<description>&lt;p&gt;Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. He
describes the options available for prophylaxis and how he treats the toxicities that do arise.&lt;/p&gt;
</description>

Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. Hedescribes the options available for prophylaxis and how he treats the toxicities that do arise.

Oncology News Central Peer-Spectives

Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC

Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC

Description